WuXi Biologics Unveils WuXiHigh™ 2.0 for Ultra-Concentrated Biologics
The Pharma Data
JULY 2, 2025
Currently, more than 20% of FDA-approved monoclonal antibodies (mAbs) fall into this category, reflecting a growing industry trend. High viscosity , aggregation risks , and stability issues often complicate both upstream and downstream processes, including manufacturing, packaging, and storage. WuXiHigh™ 2.0: WuXiHigh™ 2.0:
Let's personalize your content